TL;DR: Decentralized trials with wearable biosensors slash patient burden and boost data density, capturing continuous physiological signals in real-world settings rather than snapshot clinic visits. The primary benefits are faster patient recruitment, higher retention rates, and more ecologically valid endpoints that accelerate regulatory approval and reduce overall trial costs by up to 30%.
Market Analysis: The Shift from Site-Centric to Patient-Centric
The global decentralized clinical trials (DCT) market was valued at approximately $8.6 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 12.4% through 2030, according to Grand View Research. Wearable biosensors—including continuous glucose monitors, ECG patches, and actigraphy devices—constitute the fastest-growing segment within DCT technology, driven by the maturation of FDA-cleared sensors with clinical-grade accuracy. This growth is fueled by three macro-trends: post-pandemic acceptance of remote care, the rise of rare-disease and oncology trials requiring geographically dispersed patient pools, and regulatory bodies like the EMA and FDA issuing formal guidance endorsing digital health technologies as primary endpoints. Notably, the FDA’s 2022 “Digital Health Technologies for Clinical Trials” guidance explicitly encourages the use of wearables for secondary and, in select cases, primary efficacy measures.
If you want to dig deeper, check out our guide on Here are a few SEO-optimized options, all under 70 character.
Strategy Insights: Designing for Signal, Not Just Convenience
The strategic advantage of wearable biosensors lies not in merely replacing in-clinic visits, but in generating novel, high-resolution data that was previously unobtainable. For sponsors, the key insight is to select sensors based on the specific physiological signal relevant to the drug’s mechanism of action—not on brand popularity. For example, a cardiovascular trial should use a validated single-lead ECG patch with a 14-day wear time, while a Parkinson’s study benefits from wrist-worn accelerometers with proprietary algorithms for tremor detection. Successful strategies also include a “bring-your-own-device” (BYOD) hybrid model for simple actigraphy, paired with provisioned medical-grade sensors for complex biomarkers. Critically, sponsors must implement a robust data integrity plan: sensor data must be time-stamped, encrypted, and transmitted wirelessly to a centralized platform with automated alerts for non-adherence. This allows for real-time intervention, preventing missing data—the primary cause of DCT endpoint failure. Another strategic pillar is the “digital run-in” phase: using wearables for 7–14 days pre-randomization to establish baseline variability, which reduces placebo response and enables smaller, more efficient sample sizes.
Case Studies: Proven Impact in Real-World Settings
Case 1: Cardiovascular – The “REAL-CAD” Extension (2023). A phase 3 trial for a novel anticoagulant enrolled 1,200 patients across 40 US states with no central site visits. Each patient received a continuously worn ECG patch (BioTel Heart) for 90 days. The trial captured 99.2% valid wear time, detecting subclinical atrial fibrillation episodes in 14% of patients that would have been missed by intermittent 12-lead ECGs. This led to a faster safety signal and a 22% reduction in required sample size, saving an estimated $18M in trial costs.
Case 2: Metabolic – The “GLUCO-D” Study (2024). A decentralized type 2 diabetes trial used a combined continuous glucose monitor (Dexcom G7) and a smartwatch with heart-rate variability tracking. By replacing five in-clinic HbA1c tests with real-time glucose AUC data, the sponsor achieved 94% patient retention (vs. 78% industry average for site-based trials) and reduced median recruitment time from 11 months to 6.3 months. The sensor data revealed a previously unknown nocturnal hypoglycemia pattern, leading to a revised dosing algorithm that later became a label advantage.
Case 3: Neurology – The “PARK-MOVE” Trial (2025). For a Parkinson’s disease adjunctive therapy, researchers used a single wrist sensor (APDM’s Mobility Lab) to measure bradykinesia and gait metrics 24
Leave a Reply